A randomized, double-blind, placebo-controlled trial of the effects of green tea on lifestyle-related disease prevention and development of new green tea food enabling effective absorption 2010

A randomized, double-blind, placebo-controlled trial of the effects of green tea on lifestyle-related disease prevention and development of new green tea food enabling effective absorption 2010 - Effects of green tea on lifestyle-related disease prevention 2010

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004226

Enrollment

160

Registered

2010-09-17

Start date

2010-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

metabolic syndrome

Interventions

Take 250ml of Benihuuki green tea extracts beverage cartons three times a day (total of 750ml, the amount of catechins and caffeine are 600mg and 105 mg, respectively) for 12 weeks. Take 250ml of Beni

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: From 30 years old to 70 years old and meets at least one of the followings; 1.BMI: 23 Kg/m2 or over 2.Total-cholesterol: 200 mg/dl or more 3.LDL-Cholesterol: 120mg/dl or more

Exclusion criteria

Exclusion criteria: 1) Individuals with a medical record of heart failure or cardiac infarction. 2) Individuals judged to have atrial fibrillation, Irregular Heart Beat, hepatic damage, kidney damage, cerebrovascular accident, rheumatism, diabetes mellitus, lipid disorder and/or anemia. 3) Individuals with a medical record of allergy to food and drug. 4) Pregnant women, or women with intending to become pregnant, and lactating women. 5) Individuals judged by the doctor to be unsuitable.

Design outcomes

Primary

Measure	Time frame
1) LDL-cholesterol 2) Total cholesterol	—

Secondary

Measure	Time frame
1) body weight, waist, blood pressure 2) Serum total cholesterol, sd-LDL, triglycerides 3) FBS, HbA1c, insulin 4) high sensitive C reactive protein, catechin receptor	—

Countries

Japan

Contacts

Public ContactMitsuhiro Yamada

Kakegawa city Kakegawa city

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026